Valbiotis SAS
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France. Show More...
-
Website https://www.valbiotis.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 1.16 EUR
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share EUR -0.17 -0.67 -1.32 -1.17 -1.17 Dividends EUR Payout Ratio % * Shares Mil 4.0 4.0 4.0 5.0 7.0 Book Value Per Share * EUR 3.3 1.99 0.66 1.15 Free Cash Flow Per Share * EUR -0.09 -1.4 -1.41 Return on Assets % -42.62 -34.08 -40.35 -40.82 -40.82 Financial Leverage (Average) 4.41 1.25 1.6 1.82 1.82 Return on Equity % -265.32 -46.41 -56.55 -70.28 -70.28 Return on Invested Capital % -55.77 -36.34 -44.27 -44.29 -44.29 Interest Coverage -24.78 -31.14 -58.84 -14.37 -14.37 Current Ratio 2.71 12.0 4.36 3.66 3.66 Quick Ratio 2.71 11.77 4.25 3.52 3.52 Debt/Equity 2.11 0.15 0.31 0.45 0.45